The Diagnostic and Prognostic Value of TAT, PIC, tPAI·C and TM in Sepsis-induced Coagulopathy

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · Apr 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying various blood markers to help understand and diagnose a condition known as sepsis-induced coagulopathy (SIC), which is a serious complication that can occur in patients with sepsis. Researchers want to see how helpful certain tests are in identifying SIC in hospitalized patients who have been diagnosed with sepsis. Patients’ blood samples will be tested for specific substances within 24 hours of their sepsis diagnosis, and the results will be analyzed to see if they can effectively indicate whether a patient has SIC or not.

To be eligible for this trial, participants must be adults aged 18 and older who have been diagnosed with sepsis according to specific guidelines. Certain patients, such as those with severe liver disease or specific blood disorders, will not be included in the study. If you or a loved one participate, you will provide blood samples for testing, and the findings may contribute to better understanding and treatment of SIC in the future. Please note that this trial is not yet recruiting patients, so it may not be available for participation at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Septic patients who meet the diagnostic criteria of sepsis 3.0.
• Exclusion Criteria:
• • age \< 18 years old, heparin induced thrombocytopenia, thrombotic thrombocytopenic purpura, antiphospholipid syndrome or liver cirrhosis classified as Child-Pugh grade C and patients with a current treatment that interfered with coagulation (anticoagulants).